Spark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
August 7, 2018 7:30 AM EDTAs of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show:
A 97-percent reduction in annualized bleeding rate (ABR) and 97-percent reduction in annualized infusion rate (AIR) across all 12 participants in the studyEvidence of stable, durable expression, with no decline in plateau FVIII levels, in both participants in the 5x1011 vg/kg cohort who have been followed for greater than one year A dose response as demonstrated by FVIII expression ranging from 16 to 49 percent, with a mean of 30 percent post... More